Sarah Cannon Research Institute

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Sarah Cannon Research Institute (SCRI) is a research organization focusing on therapies for patients including drug development. With corporate headquarters in Nashville, Tennessee, United States, it conducts community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas.[1] The current CEO is Dee Anna Smith.

SCRI accrued more than 2,500 patients to cancer trials in 2009, including more than 500 to Phase I investigational studies.[2] Non-oncology trials accounted for nearly 1,500 additional patients for a total of almost 4,000.[3]

Its drug development program has conducted 70+ “first-in-man” trials. SCRI has been involved in the testing and development of about 10 drugs that have been approved since 1999.[4]

SCRI employs over 350 people [4] and was No. 4 on NashvillePost magazine’s 2010 list of the Best Employers in Middle Tennessee.[5] In 2009 [6] and 2010, SCRI was awarded a spot on Modern Healthcare’s list of the 100 Best Places to Work in Healthcare.[7]

History[edit]

SCRI was formed in 2004 through a joint venture between Tennessee Oncology and HCA. Before helping form SCRI, Tennessee Oncology had conducted research on behalf of the Minnie Pearl Research Network since 1993.[8]

SCRI started a cardiovascular initiative in 2008.[4] Currently, there are three strategic sites for cardiovascular research: Redmond Regional Medical Center in Rome, Georgia, Centennial Heart in Nashville, Tennessee, and Osceola Regional Medical Center in Kissimmee, Florida.

The Global Services division was created in 2010 to provide project management, clinical monitoring, data management, biostatistics, safety, medical writing, quality assurance and data safety monitoring boards on a global platform.[9]

Headquarters[edit]

SCRI’s headquarters are in Nashville, Tennessee, United States. Its multi-specialty division is based in Memphis, Tennessee. Sarah Cannon Research UK is headquartered in London, England.

Other locations[edit]

SCRI works with 57 sites in 24 states and the United Kingdom. This includes six oncology strategic sites and 11 multi-specialty strategic sites.

Oncology strategic sites include:

Multi-specialty strategic sites include:

References[edit]

External links[edit]